ArticleExperimental & molecular medicine2026
Gut microbiota modulation of epigenetic target EHMT2: Lacticaseibacillus rhamnosus Fb7-311 regulated renal cell carcinoma apoptosis and metastasis.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Renal cell carcinoma (RCC), also known as renal cell cancer or renal cell adenocarcinoma, is the most common type of kidney cancer and a common malignant tumor of the urinary system. Although surgical interventions and cancer treatments such as chemotherapy are commonly used to treat RCC, the persistently low 5-year survival rate and high relapse rate underscore the continued need to identify novel therapeutic targets for the development of new RCC treatments. Here, in this study, we therefore identified EHMT2 overexpression using RCC RNA-sequencing data derived from The Cancer Genome Atlas database. EHMT2 knockdown induced apoptosis and inhibited the migration/invasion of the A498 and Caki-1 RCC cell lines. Treatment with BIX-01294, an EHMT2-specific inhibitor, similarly suppressed growth and inhibited the migration/invasion of RCC cell lines, confirming the functional role of EHMT2 in RCC progression. Furthermore, DDIT3 was identified as a direct downstream target of EHMT2 and its expression was upregulated following EHMT2 downregulation by epigenetic regulation. Moreover, 3D spheroid models and in vivo experiments supported the therapeutic potential of EHMT2 as a therapeutic target for RCC treatment. In addition, by screening the components of the gut microbiota capable of modulating the EHMT2-DDIT3 axis, we identified Lacticaseibacillus rhamnosus Fb7-311, whose culture supernatant promoted apoptosis through regulation of the EHMT2-DDIT3 pathway. Thus, the development of EHMT2-specific inhibitors and the therapeutic application of L. rhamnosus Fb7-311 may represent promising strategies for effective treatment and clinical guidance of RCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.